Reading Time: 2 minutesThis week saw the publication of the Phase 2/3 trial results of the experimental drug cocktail, AMX0035, developed by the pharmaceutical company, Amylyx, and carried
Tag: Phase II
Reading Time: 5 minutesLast Thursday marked an exciting milestone in the search for effective therapies for MND as full results from the early-phase 1/2 trial of Biogen’s tofersen
Reading Time: 4 minutesOn 22 September 2014 Neuralstem announced the results from their long-term follow up of three participants who were involved in their initial phase I safety
Reading Time: 3 minutesPromising results from a Phase II clinical trial for a drug called NP001 have been announced by the biopharmaceutical company Neuraltus. The trial, conducted in America, suggested